BioCardia presented positive results from its CardiAMP Cell Therapy trial for chronic myocardial ischemia with refractory angina at EuroPCR 2026. The therapy, which uses patients' own bone marrow cells delivered via a minimally invasive procedure, significantly improved exercise tolerance by 179 seconds on average and reduced angina episodes by 82% within six months, with benefits lasting up to two years. This therapy addresses a critical unmet need for patients who have exhausted other treatment options and suffer from debilitating symptoms. The FDA has designated CardiAMP as a Breakthrough Therapy, and Medicare covers the treatment, supporting its continued clinical development and potential to improve quality of life for these patients.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
